Get the Stockscreener App
0.4502
7.90%
0.033
Pre-market:
.44
-0.0102
-2.25%
Iterum Therapeutics Plc stock is traded at $0.4502, with a volume of 680.00K.
It is up +7.90% in the last 24 hours and down -26.43% over the past month.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
See More
Previous Close:
$0.4172
Open:
$0.4105
24h Volume:
680.00K
Relative Volume:
0.76
Market Cap:
$23.76M
Revenue:
-
Net Income/Loss:
$-24.08M
P/E Ratio:
-0.5251
EPS:
-0.8572
Net Cash Flow:
$-14.75M
1W Performance:
-4.04%
1M Performance:
-26.43%
6M Performance:
-53.10%
1Y Performance:
-81.17%
1-Day Range:
$0.4105
$0.4568
1-Week Range:
$0.40
$0.50
52-Week Range:
$0.3622
$3.02
Iterum Therapeutics Plc Stock (ITRM) Company Profile
Name
Iterum Therapeutics Plc
Sector
Industry
Phone
(872) 225-6077
Address
3 DUBLIN LANDINGS, DUBLIN 1
Compare ITRM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ITRM
Iterum Therapeutics Plc
|
0.4502 | 22.02M | 0 | -24.08M | -14.75M | -0.8572 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-21 | Upgrade | Gabelli & Co | Sell → Hold |
| Mar-15-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-02-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-21-20 | Downgrade | Gabelli & Co | Buy → Sell |
| Dec-11-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-21-19 | Initiated | H.C. Wainwright | Buy |
View All
Iterum Therapeutics Plc Stock (ITRM) Latest News
Taking on analysts’ expectations and winning: Iterum Therapeutics Plc (ITRM) - Setenews
Iterum Therapeutics (ITRM) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Iterum Therapeutics Plc (ITRM) Performance and Fundamentals Dashboard tells a completely different story - Setenews
Iterum’s antibiotic ORLYNVAH now available through McKesson By Investing.com - Investing.com Nigeria
Iterum’s antibiotic ORLYNVAH now available through McKesson - Investing.com
Iterum Therapeutics (ITRM) Expands Product Availability and FDA Clearance - GuruFocus
Iterum Therapeutics Provides Business Update - The Manila Times
Iterum (NASDAQ: ITRM) Adds McKesson for ORLYNVAH as Sulopenem Disc Gains FDA 510(k) - Stock Titan
Q3 2025 Iterum Therapeutics PLC Earnings Call Transcript - GuruFocus
Is Iterum Therapeutics plc stock attractive after correctionPortfolio Update Report & Growth Oriented Trading Recommendations - newser.com
Why retail investors favor Iterum Therapeutics plc stockJuly 2025 Sentiment & Accurate Technical Buy Alerts - newser.com
Can Iterum Therapeutics plc stock maintain operating marginsJuly 2025 Weekly Recap & Trade Opportunity Analysis - newser.com
Iterum Therapeutics director Dunne buys $2,191 in shares By Investing.com - Investing.com Nigeria
Dir Dunne Buys 6,000 ($2.2K) Of Iterum Therapeutics PLC [ITRM] - TradingView
[Form 4] Iterum Therapeutics plc Insider Trading Activity - Stock Titan
Can Iterum Therapeutics plc stock resist market sell offs2025 Big Picture & Fast Gain Swing Alerts - newser.com
Why Iterum Therapeutics plc stock appeals to analysts2025 Technical Overview & High Accuracy Trade Alerts - newser.com
Combining machine learning predictions for Iterum Therapeutics plc2025 Analyst Calls & AI Enhanced Trade Execution Alerts - newser.com
Published on: 2025-11-19 01:58:59 - newser.com
Is Iterum Therapeutics plc stock attractive for long term wealth buildingQuarterly Market Review & Risk Managed Investment Strategies - newser.com
Using portfolio simulators with Iterum Therapeutics plc includedMarket Trend Report & Reliable Entry Point Alerts - newser.com
There is no way Iterum Therapeutics Plc (ITRM) can keep these numbers up - Setenews
Visualizing Iterum Therapeutics plc stock with heatmaps2025 Year in Review & Expert Verified Movement Alerts - newser.com
Will Iterum Therapeutics plc stock split attract more investorsCPI Data & Reliable Breakout Forecasts - newser.com
Iterum Therapeutics Plc Stock (ITRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):